Results 61 to 70 of about 16,411 (192)

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study

Thrombosis Journal, 2022
Background Appropriate and timely anticoagulant therapy with vitamin K antagonists (VKAs) or non-vitamin K oral antagonists (NOACs) is essential for stroke prevention in non-valvular atrial fibrillation (NVAF).
Christopher Hohmann, Magnus Lutz, Sheila Vignali, Kathrin Borchert, Karolin Seidel, Sebastian Braun, Stephan Baldus, Michael Näbauer   +7 more
doaj   +1 more source

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]

, 2017
Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core   +1 more source

Early Mobilization After Pacemaker Implantation

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The increasing use of cardiac implantable electronic devices (CIED) is leading to a rise in procedure‐related complications. Objective This trial aimed to assess the safety and feasibility of early mobilization and the possibility of same‐day discharge following permanent pacemaker implantation.
Jiří Šmíd, Vlastimil Vančura, Martin Brada, Richard Rokyta   +3 more
wiley   +1 more source

Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE

Clinical and Applied Thrombosis/Hemostasis, 2023
Patients treated with edoxaban may require diagnostic and therapeutic procedures that involve edoxaban interruption. Although heparin bridging strategies are not recommended, heparin is frequently used in clinical practice.
Amparo Santamaria MD, PhD, Cathy Chen MD, Paolo Colonna MD, FESC, Christian von Heymann MD, PhD, Manish Saxena MBBS, MSc, FBHS, Thomas Vanassche MD, PhD, James Jin PhD, Martin Unverdorben MD, PhD   +7 more
doaj   +1 more source

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures

Transfusion, EarlyView.
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea, Alex Osnis, Awan Kashoua, Orli Avnery, Gilad Itchaki, Shuli Isman, Tali Tohami, Osnat Jarchowsky‐Dolberg, Martin Ellis   +8 more
wiley   +1 more source

Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls

Research and Practice in Thrombosis and Haemostasis, 2022
Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs).
Jonathan Evrard, Romain Siriez, Céline Bouvy, Julien Favresse, Halil Yildiz, Philippe Hainaut, François Mullier, Jean‐Michel Dogné, Jonathan Douxfils   +8 more
doaj   +1 more source

Advances in cardiac devices and bioelectronics augmented with artificial intelligence

The Journal of Physiology, EarlyView.
Abstract figure legend Interfaces between the human heart, diagnostic bioelectronics, artificial intelligence, and clinical care. From left to right: Human heart and biosensor interface; representative waveforms of common diagnostic bioelectronic sensing modalities.
Charles Stark, Eric Rytkin, Andrei Alexandru Mircea, Igor R. Efimov   +3 more
wiley   +1 more source

Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis

JACC: Advances
Background: The ONCO DVT study revealed that 12-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (IDDVT) was superior to 3-month edoxaban treatment.
Tomoyuki Nagai, MD, Naohiko Nakanishi, MD, Yugo Yamashita, MD, Takeshi Morimoto, MPH, MD, Nao Muraoka, MD, Michihisa Umetsu, MD, Yuji Nishimoto, MD, Takuma Takada, MD, Yoshito Ogihara, MD, Tatsuya Nishikawa, MD, Nobutaka Ikeda, MD, Kazunori Otsui, MD, Daisuke Sueta, MD, Yukari Tsubata, MD, Masaaki Shoji, MD, Ayumi Shikama, MD, Yutaka Hosoi, MD, Yasuhiro Tanabe, MD, Ryuki Chatani, MD, Kengo Tsukahara, MD, Kitae Kim, MD, Satoshi Ikeda, MD, Takeshi Kimura, MD, Satoaki Matoba, MD   +23 more
doaj   +1 more source

Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]

, 2017
A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto, Alvarado Lorenzo, Alfonso, Curto Aguilera, Adrián   +2 more
core   +2 more sources

Suspected Cardioembolic Stroke Linked to Left Atrial Stunning After Pulsed Field Ablation for Atrial Fibrillation

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
After pulsed field ablation with pulmonary vein and posterior wall isolation, a patient developed ischemic stroke due to left carotid artery occlusion. Pathology of the retrieved thrombus revealed an acute red thrombus, suggesting left atrial stunning–induced thrombus formation.
Akinori Matsushima, Takamichi Katsuhara, Tomonobu Kodama, Kenta Uto, Yasuo Okumura   +4 more
wiley   +1 more source